The Bristol-Myers Squibb Co. Logo

The Bristol-Myers Squibb Co. Logo

Daniel Acker/Bloomberg

Investors should buy Bristol-Myers Squibb Co. calls as approval for a melanoma treatment may boost the drugmaker’s stock price, Goldman Sachs Group Inc. said.